About our company
GREINER BIO-ONE IS MAKING A DIFFERENCE
Our performance in 2024
Compared to 2023, our customers' stock levels have increasingly eased in 2024, resulting in a more balanced demand situation.
The Preanalytics business unit recorded satisfactory demand overall, and in the BioScience segment, demand stabilized after a significant decline in the previous year and the first half of the current year.
Outlook for 2025: Profitable growth
This year, Greiner Bio-One remains focused on profitable growth and looks ahead with confidence to the economic developments of 2025.
The stabilization of the market situation in recent months provides a solid foundation for this. In the Preanalytics and BioScience business units, Greiner Bio-One is building on its core products to further strengthen its market position. Beyond its home markets in Europe, the company sees significant potential in the United States, aiming to further expand its global market share, particularly in BioScience.
Greiner Bio-One is also optimistic about the future of its Sterilization business unit, with its subsidiary Mediscan and the site expansion in Kremsmünster, Austria. With this investment in state-of-the-art plant technology, Mediscan is well-positioned to meet the growing demand from third-party customers in the sterilization sector.
“Our initiatives have set the stage for sustainable and profitable growth, allowing us to make a meaningful impact for users and patients.”
Turnover
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Turnover | 473.0 | 509.0 | 693.0 | 695.0 | 693.0 | 637.0 | 666.0 |
Greiner Annual and Sustainability Report
Greiner Bio-One Company Movie
To us, health is the highest personal priority. This inspires our daily mission of serving life sciences and healthcare professionals with advanced and sustainable products and solutions. It is the passion and dedication of our people that make the difference. With a straightforward approach our global team continuously strives for excellence and closely collaborates with our customers. That is where our product solutions for preanalytics, research and biotechnology come in. We’re here for you worldwide, right where you need us.
Core Business
Greiner Bio-One has been developing and distributing solutions and high-quality plastic products for medical technology and laboratory applications for more than 60 years. Its products are used in clinical diagnostics (e.g. blood and saliva collection systems), life science research (e.g. cell culture products), drug discovery (e.g. microplates), and the sterilization of medical devices. With a broad portfolio available in over 100 countries worldwide, the company supports scientists and medical professionals in their daily work caring for patients. Greiner Bio-One operates in the market through its three business units:
Preanalytics → develops and manufactures systems for taking blood and urine samples from people and animals. It also provides digital systems for pre-analytics. Indwelling venous safety cannulas round out the portfolio. The innovative product solutions from Preanalytics significantly improve the efficiency and safety of daily routine tasks in a hospital, laboratory, or clinical setting. This division also covers customised software solutions Tracie Healthcare Solutions which ensure greater efficiency and patient safety in the preanalytical process.
Mediscan → is one of Europe’s leading suppliers and service providers in the sterilization of medical products, the sterilization of food packaging, and the functional improvement of plastics and semiconductors using ionizing radiation.
BioScience → is a strong technology partner for universities, research institutions, and players in the diagnostic,
pharmaceutical, and biotech fields. The business unit focuses on developing and producing laboratory quipment, such as containers for cultivating and analyzing cell cultures, as well as microplates used for high-throughput screening in biochemical, genetic, and pharmacological tests.
As an Original Equipment Manufacturer (OEM), Greiner Bio-One is also a solid partner for industry clients working in pharmaceuticals, biotechnology, diagnostics and medical technology and offers customised design development and production processes.
“Our central objective is to ensure that: We embody our values and our conduct is legally and ethically impeccable! The Management Board will do everything in its power to ensure that the standards established in this code of conduct are permanently implemented and respected in all parts of the Group. ”
The Greiner Group, with almost 150 years of history, has become a real global player in the past few years. With more than 125 sites across the globe, we are close to our customers and can flexibly respond to their needs. However, such a complex organisation also presents challenges.
We would like this code of conduct to serve as a basis on which our company’s positive development can continue in the long term. The code is rooted in the Greiner philosophy, which focuses on the global orientation of the Group, its attractiveness as an employer and service provider, and excellent conduct. We have set the rules of conduct derived from these principles in stone in the code of conduct and made them available to all employees, customers, and business partners. It should help us to guarantee the integrity of our conduct in the long term.
Our central objective is to ensure that: We embody our values and our conduct is legally and ethically impeccable!
The Management Board will do everything in its power to ensure that the standards established in this code of conduct are permanently implemented and respected in all parts of the Group. It is our deliberate wish and declared aim to set a good example. We invite all employees to join us on this path.
Research and development have always been among the drivers for growth in any economic system. Medical technology and biotechnology in particular have, over the last few decades, experienced steady upwards growth.
The commercial success of Greiner Bio-One is based upon the consistent advancement of modern technologies and techniques. A significant proportion of the company's turnover is invested in R&D. At the company's facilities in Austria and Germany, teams of product specialists from all manner of different disciplines are working on designing and implementing innovative solutions.
At Greiner Bio-One, specialists in microbiology, chemistry, physics and plastics engineering work on the development of new processes and products. Greiner Bio-One has its own state-of-the-art research centre in Kremsmünster (Upper Austria) for the development of molecular biology analysis methods based on DNA arrays. Clinical studies are prepared and performance assessment testing carried out in the company's own clinical laboratory.
Extensive networks incorporating selected partner firms, public institutions and organisations mean that Greiner Bio-One is always able to identify relevant issues, the latest developments and emerging trends early and then translate them into product solutions.
As a supplier of high-quality products for medical research and manufacturers of diagnostic agents, we bear responsibility for countless analyses that are carried out worldwide in research organisations, laboratories and hospitals using our products. We regard our customers' confidence for 50 years as testimony to the superlative quality standard we offer and also as an obligation to continue improving the quality of our products even further.
Quality comes first at Greiner Bio-One. Our products are expected to deliver the highest quality. All production sites are ISO 9001 and ISO 13485 certified. We also meet countless national and international quality requirements. By using state-of-the-art production technologies, manufacturing under special environmental conditions and deploying highly skilled staff, we are able to continuously improve the quality of our products and processes.
Greiner Bio-One applies a carefully developed quality assurance system to fully meet all customer requirements. Our optimised processes encompass the entire supply chain, starting from careful selection of suppliers through development and product realisation to the controlled sale of our products. All products are labelled in accordance with the applicable statutory provisions and can be traced back to the components and suppliers used.
The products and process are regularly audited by national and international authorities and authorisation bodies. Each stage of production is constantly and systematically monitored by our staff, to ensure excellent product quality, determine where improvements can be made and optimise this potential. We strive to optimise all processes to the benefit of our customers. Risk management is a core element of our approach to quality.
The best quality management system is only as good as the people who apply it. Special focus is placed on the training, qualification and continued development of the entire Greiner Bio-One team. We regularly hold quality and product training sessions for our staff, at which they are shown how all Greiner Bio-One products are used, and the resulting quality requirements. Through these measures, we can achieve the highest quality standards for our customers on a day-to-day basis.
